Dapoxetine is the International Nonproprietary Name of a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. It is currently in Phase III of the approval process. Function If approved, this would make Dapoxetine join the ranks of erectile dysfunction drugs such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra),… (More on Dapoxetine)